We are live on ! Find out more
ISEE

IVERIC bio, Inc. Common Stock

Delisted

ISEE was delisted on the 10th of July, 2023.

52 hedge funds and large institutions have $21.2M invested in IVERIC bio, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

10% less funds holding

Funds holding: 5852 (-6)

10% less capital invested

Capital invested by funds: $23.7M → $21.2M (-$2.47M)

44% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 18

55% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 11

Holders
52
Holders Change
-6
Holders Change %
-10.34%
% of All Funds
1.13%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
5
Increased
10
Reduced
18
Closed
11
Calls
Puts
Net Calls
Net Calls Change

ISEE Hedge Fund Activity: Q2 2019 in Review

52 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q2 2019, worth a combined $21.2M — down 10% from $23.7M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ISEE and 5 opened new positions — a net loss of 6 holders — while 18 trimmed existing stakes and 10 added.

The largest buyer was Assenagon Asset Management, opening a new position worth an estimated $320K. The largest seller was Morgan Stanley, cutting an estimated $309K.

  • 52 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q2 2019, down from 58 in Q1 2019.
  • Funds reported $21.2M of IVERIC bio, Inc. Common Stock stock for Q2 2019, down 10% quarter-over-quarter.
  • 5 funds opened new IVERIC bio, Inc. Common Stock positions in Q2 2019 and 11 closed out, a net change of -6 holders.
  • The largest IVERIC bio, Inc. Common Stock buyer in Q2 2019 was Assenagon Asset Management, an estimated $320K added.
  • The largest IVERIC bio, Inc. Common Stock seller in Q2 2019 was Morgan Stanley, an estimated $309K sold.

Based on aggregated 13F filings for Q2 2019.